An interventional study of Pharmacist-led antimicrobial therapy optimization in Infections, Bacterial Infections and Critical Illness, sponsored by Clinica las Condes, Chile. Completed at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Clinica las Condes, Chile · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bacterial Infections with a site in Chile — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Chile.
Among the 11 studies in Bacterial Infections with a site in Chile, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 11th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →None of the 11 studies in Bacterial Infections with a site in Chile is open now. The open studies under Bacterial Infections, anywhere →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 440 across the 10 interventional studies, 2,233 across the 1 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 9 most frequent:
Clinica las Condes, Chile is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Clinica las Condes, Chile has 1 study filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Bacterial Infections with a site in Chile, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inappropriate antimicrobial prescribing is common in hospitalised patients and is associated with worse outcomes. Clinical pharmacists are core members of antimicrobial stewardship teams, but the evidence comes almost entirely from intensive care units and from undifferentiated hospital-wide analyses.
This trial tested whether adding pharmacist-led antimicrobial therapy optimization to standard care improves the quality of antibiotic prescribing in an intermediate care unit, a setting where antimicrobial therapy is often the main therapeutic intervention.
Adults admitted with an active infection and antibiotics started within the previous 72 hours were randomly assigned to standard care or to standard care plus a structured daily pharmacist review of five prescribing domains during the first four days. The primary outcome was optimal prescribing at day 4, defined as meeting all five domains simultaneously.
The intervention consisted of a structured daily review of indication, spectrum selection, dose and frequency, route of administration and duration of therapy.
Dose optimisation included therapeutic drug monitoring of vancomycin and amikacin, adjustment for renal function and renal replacement therapy, weight-based and albumin-guided correction, and extended or continuous infusion of beta-lactams where pharmacokinetic optimisation was indicated.
Recommendations were directed to the attending physician, who decided whether to implement them. The pharmacist did not modify prescriptions independently. Acceptance was defined as implementation documented in the electronic health record within 24 hours of communication.
After the day 4 assessment, participants in both arms could receive pharmaceutical intervention as clinically indicated.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
This study's enrollment of 180 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Browse Bacterial Infections studies →Clinica las Condes, Chile is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Compared within Bacterial Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard care plus pharmacist-led antimicrobial therapy optimization, with structured daily review of five prescribing domains during the first four days from randomisation.
Other: Pharmacist-led antimicrobial therapy optimization
Standard medical care according to institutional protocols, with no pharmaceutical intervention during the first four days from randomisation. From day 4 onwards, participants in this arm could also receive pharmacist-led optimization.
Structured daily review of indication, spectrum selection, dose and frequency, route of administration and duration of antimicrobial therapy, delivered as recommendations to the attending physician.
Also known as: ATO
Optimal antibiotic prescribing
Proportion of participants whose antibiotic prescription simultaneously met all five standardised criteria: appropriate indication, correct spectrum coverage, adequate dose and frequency, suitable route of administration and appropriate duration. A prescription failing any single domain was classified as optimizable.
Time frame: Day 4 after randomisation
Favourable clinical response
Composite requiring all of: reduction of 50 percent or more in procalcitonin or an absolute value below 0.5 ng/mL, or reduction of 50 percent or more from peak C-reactive protein; decrease in symptoms of infection in the treating physician's opinion; decrease in the temperature curve from the thermal maximum; absence of hypothermia (temperature 35 degrees Celsius or above); white blood cell count below 11 x 10\^9/L; and no change in antimicrobial therapy involving escalation.
Time frame: Day 7 after randomisation
Acceptance of pharmacist recommendations
Number of recommendations implemented and documented in the electronic health record within 24 hours of communication, divided by the total number of recommendations made.
Time frame: Days 1 to 4 after randomisation
Days of therapy
Sum of days on which each individual antibiotic was received, regardless of dose, reported per participant and standardised per 1,000 patient-bed-days.
Time frame: From randomisation to the end of antibiotic treatment, up to 60 days
Antibiotic-related adverse reactions
Adverse reactions recorded in either arm as a reason for modifying antimicrobial therapy. Ascertainment was limited to reactions severe enough to prompt a change in treatment.
Time frame: From randomisation to the end of antibiotic treatment, up to 60 days
Clinical cure
Complete resolution of the signs and symptoms of infection.
Time frame: End of antibiotic treatment or hospital discharge, whichever occurred first, up to 60 days
All-cause mortality
Death from any cause, assessed in hospital and at 28 and 90 days.
Time frame: From randomisation to hospital discharge, up to 60 days; Day 28 after randomisation; Day 90 after randomisation
Clinical deterioration requiring escalation of care
Deterioration of the clinical condition requiring an increase in the level of care.
Time frame: From randomisation to hospital discharge, up to 60 days
Transfer to intensive care
Transfer from the intermediate care unit to an intensive care unit.
Time frame: From randomisation to hospital discharge, up to 60 days
Hospital length of stay
Total days of hospitalisation from admission to discharge.
Time frame: From admission to discharge, up to 60 days
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Feb 2025, 11 months.
Of 57 non-industry interventional studies with no phase under Bacterial Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 11 months is below that.
Counting every sponsor, half of 61 studies reached it within 24 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinica las Condes, Chile